Lizhi Zhang
Biochemistry, Genetics and Molecular Biology · The Ohio State University
Publications
46
Citations
5,010
Est. group size
—
Recurring co-author estimate
Active years
32
Publishing since 1994
This publication record appears to span a mix of topics including pancreatic cancer molecular biology (genes like KRAS, GLI2, CLPTM1L, and metabolic enzymes), stroke-related injury mechanisms, bone density genetics, and general clinical/epidemiological studies. Many recent entries are supplementary data files linked to pancreatic cancer studies rather than standalone research articles, making it difficult to identify a single consistent research focus from this record. Prospective students should note that the bibliographic data suggests this may represent contributions to multiple distinct projects or collaborations rather than one continuous research program.
Publication output was low and steady from 2017-2022 (1-3 per year) before a sharp spike in 2023 (13 items, largely supplementary materials), followed by a decline in 2024-2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Relationship between the atherogenic index of plasma and arthritis in American adults: Findings from the National Health and Nutrition Examination Survey 2005–2018
Journal of International Medical Research · 2025
- Study on the risk identification of abnormal gas outbursts based on the mechanism of biological immunity
Scientific Reports · 2025
- Morphological findings in different subtypes of hepatic amyloid
Human Pathology · 2024
- Supplementary Figure 7 from KRAS Promotes GLI2-Dependent Transcription during Pancreatic Carcinogenesis
2024
- Supplementary Figure 7 from KRAS Promotes GLI2-Dependent Transcription during Pancreatic Carcinogenesis
2024
- Supplementary Materials and Methods from Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1–MAPK Interaction
2023
- Supplementary Table S2 from Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1–MAPK Interaction
2023
- Supplementary Figure 4 from CLPTM1L Promotes Growth and Enhances Aneuploidy in Pancreatic Cancer Cells
2023
- Supplementary Figure 5 from CLPTM1L Promotes Growth and Enhances Aneuploidy in Pancreatic Cancer Cells
2023
- Supplementary Figure 6 from CLPTM1L Promotes Growth and Enhances Aneuploidy in Pancreatic Cancer Cells
2023
- Supplementary Figure 2 from CLPTM1L Promotes Growth and Enhances Aneuploidy in Pancreatic Cancer Cells
2023
- Supplementary Figure 4 from CLPTM1L Promotes Growth and Enhances Aneuploidy in Pancreatic Cancer Cells
2023
- Supplementary Figure 1 from CLPTM1L Promotes Growth and Enhances Aneuploidy in Pancreatic Cancer Cells
2023
- Supplementary Figure 6 from CLPTM1L Promotes Growth and Enhances Aneuploidy in Pancreatic Cancer Cells
2023
- Data from CLPTM1L Promotes Growth and Enhances Aneuploidy in Pancreatic Cancer Cells
2023
- Zhongguo Yaolixue Tongbao×2
- Figshare×2
- Cell×1
- Cell Reports×1
- Journal of Clinical Investigation×1
- Yiting Li
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Anne M. Strohecker
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Arturo Orlacchio
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Swetha Rajasekaran
Medicine · The Ohio State University
- Alessandro La Ferlita
Biochemistry, Genetics and Molecular Biology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile